{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:12:12Z","timestamp":1776435132765,"version":"3.51.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-022-00697-3","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:21:20Z","timestamp":1656919280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-4873","authenticated-orcid":false,"given":"Andrew","family":"Staron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-4590","authenticated-orcid":false,"given":"Luke","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe","family":"Doros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"697_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00385-0","volume":"10","author":"A Staron","year":"2020","unstructured":"Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020;10:118 https:\/\/doi.org\/10.1038\/s41408-020-00385-0","journal-title":"Blood Cancer J"},{"key":"697_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10552-015-0685-2","volume":"27","author":"ME VanValkenburg","year":"2016","unstructured":"VanValkenburg ME, Pruitt GI, Brill IK, Costa L, Ehtsham M, Justement IT, et al. Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control. 2016;27:81\u201391. https:\/\/doi.org\/10.1007\/s10552-015-0685-2","journal-title":"Cancer Causes Control"},{"key":"697_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0132-1","volume":"8","author":"LB Baughn","year":"2018","unstructured":"Baughn LB, Pearce K, Larson D, Polley MY, Elhaik E, Baird M, et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 2018;8:96 https:\/\/doi.org\/10.1038\/s41408-018-0132-1","journal-title":"Blood Cancer J"},{"key":"697_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0177-9","volume":"9","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian D, Hill E, Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, et al. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer J. 2019;9:15 https:\/\/doi.org\/10.1038\/s41408-019-0177-9","journal-title":"Blood Cancer J"},{"key":"697_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/bloodadvances.2019000491","volume":"4","author":"Z Du","year":"2020","unstructured":"Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, et al. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020;4:181\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2019000491","journal-title":"Blood Adv"},{"key":"697_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","volume":"22","author":"C Gasparetto","year":"2022","unstructured":"Gasparetto C, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, et al. Effect of t (11;14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry. Clin Lymphoma Myeloma Leuk. 2022;22:149\u201357. https:\/\/doi.org\/10.1016\/j.clml.2021.08.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"697_CR7","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/blood-2007-11-122101","volume":"111","author":"T Bochtler","year":"2008","unstructured":"Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood. 2008;111:4700\u20135. https:\/\/doi.org\/10.1182\/blood-2007-11-122101","journal-title":"Blood"},{"key":"697_CR8","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood-2015-10-673095","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127:3035\u20139. https:\/\/doi.org\/10.1182\/blood-2015-10-673095","journal-title":"Blood"},{"key":"697_CR9","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/bloodadvances.2018023200","volume":"2","author":"T Bochtler","year":"2018","unstructured":"Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Kr\u00e4mer A, et al. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv. 2018;2:2607\u201318. https:\/\/doi.org\/10.1182\/bloodadvances.2018023200","journal-title":"Blood Adv"},{"key":"697_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","volume":"27","author":"B Dumas","year":"2020","unstructured":"Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid. 2020;27:244\u20139. https:\/\/doi.org\/10.1080\/13506129.2020.1778461","journal-title":"Amyloid"},{"key":"697_CR11","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1038\/bcj.2015.34","volume":"5","author":"R Warsame","year":"2015","unstructured":"Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015;5:e310\u2013e310. https:\/\/doi.org\/10.1038\/bcj.2015.34","journal-title":"Blood Cancer J"},{"key":"697_CR12","doi-asserted-by":"publisher","unstructured":"Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t (11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33:1371\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.57.4947","DOI":"10.1200\/JCO.2014.57.4947"},{"key":"697_CR13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","volume":"128","author":"T Bochtler","year":"2016","unstructured":"Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128:594\u2013602. https:\/\/doi.org\/10.1182\/blood-2015-10-676361","journal-title":"Blood"},{"key":"697_CR14","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S2152-2650(21)02108-X","volume":"21","author":"S Kumar","year":"2021","unstructured":"Kumar S, Dispenzieri A, Bhutani D, Gertz M, Wechalekar A, Palladini G, et al. OAB-034: evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. Clin Lymphoma Myeloma Leuk. 2021;21:S22 https:\/\/doi.org\/10.1016\/S2152-2650(21)02108-X","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"697_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajh.26399","volume":"97","author":"RE Szalat","year":"2022","unstructured":"Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab. Am J Hematol 2022;97:79\u201389. https:\/\/doi.org\/10.1002\/ajh.26399","journal-title":"Am J Hematol"},{"key":"697_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.leu.2403586","volume":"19","author":"S Wuilleme","year":"2005","unstructured":"Wuilleme S, Robillard N, Lod\u00e9 L, Magrangeas F, Beris H, Harousseau JL, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19:275\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2403586","journal-title":"Leukemia."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00697-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:09:45Z","timestamp":1669234185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00697-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00697-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}